Two stages across two days at Nakanoshima Qross. The Frontier Stage carries the full program of keynotes, NGL Boardrooms and clinical sessions; the Build Stage runs each afternoon alongside it with the science, concepts and practical starting points for building in the field.
This agenda is a working version and subject to change. Session times, formats and speakers will be confirmed closer to the conference.
Keynotes, NGL Boardrooms and clinical sessions across two full days, opening with a pre-conference evening on Wednesday, October 14.
Selected startups pitch their vision for the next generation of health and longevity.
An informal opening gathering for speakers, attendees and partners.
Location to be announced.
A morning ritual of matcha, mindfulness and connection.
Prompt start.
Four Paths to the Same Clinic
Four physicians reveal the distinct paths, philosophies and clinical models that brought them into longevity medicine, and where their approaches converge or differ.
A rapid discussion separating established physiology from persistent myths while examining how science, clinical practice and policy are reshaping the hormone conversation across the healthspan.
Measuring the Three Diseases That End Most Lives, and Treating to What We Find
One Patient. Four Systems. Infinite Interactions.
Leading longevity clinicians and scientists evaluate the same complex patient through the interconnected lenses of brain, heart, gut and hormonal health. Each participant must prioritize risk, determine what matters first and defend a treatment strategy.
A live conversation on what the biology of aging tells us today, which mechanisms matter most, and where intervention may realistically alter trajectory.
A focused discussion on what is scientifically credible, clinically actionable and ready for responsible translation in regenerative and cellular medicine.
A discussion of how Japan and other global markets are balancing scientific evidence, patient access, regulatory flexibility and clinical responsibility in regenerative medicine.
How communication among the nervous, immune and endocrine systems may influence inflammation, resilience and the trajectory of aging.
A discussion of traditional medical systems, contemplative practices, consciousness and psychedelics, and what remains meaningful when examined through the lens of modern science.
Closing Day 1 with a look toward what comes next: how Hims & Hers, a global company now serving longevity care around the world, is poised to become the first global company to do so, and what that means for the field.
As the science of aging becomes increasingly actionable, the challenge moves beyond whether we can influence healthspan to what happens when we translate those discoveries across populations, healthcare systems and societies.
What Survives When the Luxury Stack Disappears?
By 2050, more than two billion people will be over 60, with most living in low- and middle-income countries. Participants are challenged to design a minimum viable longevity system for a resource-constrained health system: what stays, what goes, what should be measured and where limited resources should be deployed first.
AI, Longevity and the Future Physician
An interactive examination of how AI may reshape medicine, from interpreting increasingly complex biological data to changing the physician-patient encounter itself.
Where can AI meaningfully support clinical reasoning and diagnostics, and what should remain under physician judgment?
A Mayo Clinic case study exploring whether technology can move the clinical encounter away from documentation and toward greater understanding, trust and interaction.
An exploration of what changes when AI is no longer simply a tool the physician consults, but an active presence in the clinical environment.
The Boardroom concludes by bringing participants together around the evolving role of AI, physician judgment and the future clinical encounter.
Are aging biomarkers now reliable, responsive and clinically useful enough to guide prevention? An examination of what these tools can measure today, how they respond to intervention and where their limitations remain.
Life insurance has traditionally priced the risk of illness and death. Could biological-age testing allow insurers to become active partners in prevention? This session explores how epigenetic testing is being applied, what incentives it could create and what implementation might look like in practice.
Could Japan combine aging biomarkers, preventive care and insurance incentives into a scalable longevity model? A focused discussion of what could be implemented, who would pay and what infrastructure and partnerships would be required.
A telehealth platform, consumer health brand and diagnostics company are each racing to become the patient’s front door for longevity. The strategic question is whether they compete to own the entire relationship or interoperate and divide the value, and where durable value ultimately accrues as longevity scales.
Evening free for participants to explore Osaka. Restaurant, cultural and neighborhood recommendations will be available on the conference website.
Continue to the afternoon stage that runs alongside the Frontier Stage.
Build Stage agendaFor those new to the field who want to build their foundation, this afternoon track runs alongside the Frontier Stage and covers the essentials: the science, concepts, and practical starting points for anyone looking to understand or build within Japan’s blooming longevity market.
Runs each afternoon, in parallel with the Frontier Stage talks. Come for a single session or stay for the whole track — no prior background required.
Every session is designed to stand on its own, so you can move between the Build Stage and the Frontier Stage based on your interests.
Foundations builds the models needed to translate geroscience to humans. Technology makes it usable for one person with precision. Access allows it to scale across the globe.
Dr. Maier lays out the fundamentals: what geroscience is, the hallmarks of aging, chronological vs. biological age, and how longevity medicine differs from conventional sick care. She covers how biomarkers of aging are measured and used to guide individualized prevention strategies, and traces the translational bridge from research to clinical practice.
Suzuki walks through how autophagy is actually measured in humans today, which intervention strategies — dietary, supplement, pharmacological — are furthest along and most clinically actionable right now, and what it took to move from a university lab to a real product pipeline.
Dr. Fransén has years of experience analyzing the longevity biotech market and provides a clinician-scientist’s lens on which drugs are best positioned for clinical impact.
Dr. Molina’s work sets the standardized protocols, multi-omics analysis, and functional tests used to measure functional age-reversal in muscle, cognitive, and immune function in the $101M XPRIZE Healthspan. Together, they shift the conversation from “what’s the next blockbuster longevity drug” to “how would we know it worked.”
Dr. Grady walks through how to decode an individual’s gut microbiome, connecting it to current science on GI, metabolic, autoimmune, neurological, and longevity-related outcomes. He makes the case for the gut as an actionable diagnostic layer, and for AI as the tool that lets you apply insights with precision for personalized prevention.
Elise Lilliehöök highlights evidence that social relationships are one of the strongest, most ancient predictors of a long life. She makes the case for treating loneliness and social disconnection as a measurable, addressable longevity risk factor, and shows how technology can be designed to create deeper human connection rather than substitute for it.
How can virtual care make preventive health services easier to reach and use? This session examines the patient journey from first contact to ongoing care, focusing on access, clinical trust, clinical effectiveness, and the practical challenges of delivering a consistent experience at scale.
Tim Doyle walks through what it takes to scale GLP-1 telehealth access in Japan’s insurance-driven, clinical guideline-gated system. He makes the case for the emerging “GLP-1 moment” in Japan and what builders and clinicians should watch as the landscape continues to evolve and open new opportunities.
Popa walks through the operator’s view of what it takes to invest in and open a longevity clinic: infrastructure costs, unit economics, and the practical steps and logistics from idea to first patient.
Dr. Kennedy closes Day 1 by walking through the development of biological age clocks, the different types, and speaking candidly about where clocks are ready for the clinic and where the field still needs more evidence.
Julie Baron picks up directly from there with LinAge2, showing where it translates in the real world and exactly how a biological-age score becomes a concrete, personalized action plan.
Why NGL chose Japan: the global longevity imperative, and why Japan’s combination of the world’s most advanced aging demographics, a sophisticated functional-food and regenerative-medicine framework, and a clear two-track regulatory pathway positions it as a central node for the Asia-Pacific longevity market — arguably the earliest, highest-signal one globally.
What separates a promising supplement concept from a durable business? Dr. Krishnan explores product development, scientific differentiation, practitioner education, and distribution, focusing on how companies can communicate evidence clearly and build trust in a crowded market.
Dr. Husain covers cardiovascular-specific aging patterns, their systemic ripple effects, and the integrative cardiology strategies he uses to protect heart health before disease appears.
Dr. Lesslar, a physician specializing in psychoneuroimmunology, opens with how the nervous, immune, and endocrine systems physically cross-talk, the pathways that connect brain and immune aging, and what that means for intervention strategies.
Dr. Molina follows with the validation question underneath it all: how do we actually measure whether a brain- or immune-targeted intervention worked? He walks through the standardized methods, multi-omics measurement, and functional testing benchmarks utilized in the global XPRIZE Healthspan Competition.
A live demo of wearable “frequency technology” for nervous-system regulation from Dmitri Leonov, founder of OneDevice and former U.S. lead for Taopatch.
This session presents the evidence for declining testosterone and estrogen as independent, measurable drivers of cardiovascular disease, osteoporosis, metabolic disease, and cognitive decline, and why treating them early is prevention, not quality-of-life care.
Dr. Shah brings the men’s-health and regulation/access lens; Dr. Ofra Castro Wersäll discusses the estrogen side for women’s healthspan. Together they cover where HRT fits in longevity strategies, where regulation has lagged, what access looks like in practice today, and where the opportunity is for anyone building in this space.
Dr. Bhargava covers where AI delivers value in longevity medicine today, where the real bottlenecks remain, and why “more data” hasn’t solved them on its own.
Dr. Midori Meshitsuka has treated 10,000+ patients with stem-cell, exosome, and peptide-based regenerative therapies; she speaks to what the frontier looks like within a working clinic and separates the hype from the real clinical applications.
Back to the full Frontier Stage program.
Frontier Stage agenda